CytoSorbents Corporation (CTSO)

[techxen]

DIC apparently has long been associated with increased mortality in patients with sepsis, but I had to look it up to get a better understanding.

From my earlier post I meant 2015 Users Meeting - here is the official literature which is much more legible and professionally formatted. Those two case studies from Austria (Klaus Krenn) are on page 15.
http://cytosorbents.com/wp-content/uploads/2016/03/Proceedings%202nd%20Int%20Users%20Meeting%202015_EN.pdf

There was a specific Cytosorb case published for DIC but I was not able to get it to retrieve properly on the company's web site.
Successful treatment of severe sepsis with disseminated intravascular coagulopathy
http://cytosorb-therapy.com/infoitem/successful-treatment-severe-sepsis-disseminated-intravascular-coagulopathy/

I think what you have seen in the recent activity with the stock was from the announcement of the expansion for the EU approved indications to include myoglobin removal. Cytosorb has proven case studies in which demonstrate its excellent myoglobin binding properties.

There are numerous cases and information published on the company's web site involving rhabdomyolysis and the presence of myoglobin. I would encourage you to read some of these if you are new to the company or technology.
http://cytosorb-therapy.com/?s=myoglobin